Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 2, 2026

Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement

View original at globenewswire.com
Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement MIDLAND, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MAWSON INFRASTRUCTURE GROUP Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Endeavor purported combined ownership of shares amounting to 48.0% of shares outstanding as of January 28, 2026

    80% confidence
  • The Rights Agreement does not preclude the Board from considering proposals, engaging in discussions or pursuing transactions that it believes are in the best interests of Mawson and its stockholders

    80% confidence
  • Endeavor purported combined ownership of shares amounting to 31.6% of shares outstanding as of January 6, 2026

    80% confidence
  • Based on Mawson's records, Endeavor's purported 48.0% ownership actually amounted to 29.7% of shares outstanding

    80% confidence
  • Based on Mawson's records, Endeavor's purported 31.6% ownership actually amounted to 19.5% of shares outstanding

    80% confidence
  • The Rights Agreement is intended to enable Mawson's stockholders to realize the long-term value of their investment and protect its stockholders from actions of third parties that the Board determines are not in the best interests of Mawson and its stockholders

    80% confidence
  • Endeavor did not have any present plan or proposal that would result in an extraordinary corporate transaction or a change in the Board or management of the Company

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com